WASHINGTON, DC (December 3, 2025) – United for Cures, a collaborative of patients and patient advocacy organizations, announced today that the Federation of American Societies for Experimental Biology (FASEB) is now a supporter of United for Cures’s efforts to increase funding for lifesaving medical research that leads to breakthrough treatments and cures.

“FASEB and our 22 member societies are committed to advancing the basic and translational research that drives the development of new treatments and cures,” said Dr. Eric E. Kelley, President of FASEB. “The work that our members do every day serves to support and promote medical breakthroughs that improve and save lives. We are pleased to support United for Cures as its mission aligns closely with our commitment for compelling Congress to increase funding for medical research, which promotes scientific innovation and discovery and delivers tangible benefits for patients.” 

“Basic research is the foundation of every treatment and cure that patients rely on,” said Russ Paulsen, leader of United for Cures. “FASEB’s support underscores the critical connection between robust funding for basic research and better outcomes for patients. We are grateful for their commitment and for the work their members do that translates to helping people live longer, healthier lives.”

###

About United for Cures
United for Cures is a collaborative of patients and patient advocacy organizations dedicated to protecting lifesaving medical research that has—for decades—been leading the world in delivering treatments and cures in communities across the United States.  

About FASEB

FASEB is comprised of 22 scientific member societies with 110,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB’s mission is to advance health and well-being by promoting research and education in biological and biomedical sciences through collaborative advocacy and service to member societies and their members. Visit faseb.org for more information.